BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 17578360)

  • 1. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.
    Hum Reprod; 2000 Jul; 15(7):1446-51. PubMed ID: 10875887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
    Orvieto R; Nahum R; Rabinson J; Ashkenazi J; Anteby EY; Meltcer S
    Fertil Steril; 2009 Apr; 91(4 Suppl):1522-5. PubMed ID: 18851846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
    Šprem Goldštajn M; Dumančić S; Mikuš M
    J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.
    Bosch E; Escudero E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2005 Nov; 84(5):1529-32. PubMed ID: 16275263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
    Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
    Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.
    Hugues JN; Cédrin-Durnerin I; Howles CM; ; Amram M; Angelini A; Balen A; Barbereau D; Birkhauser M; Boujenah A; De Leo V; De Placido G; Dessole S; Favrin S; Ferrazi E; Gay C; Germond M; Hedon B; Hocke C; Jolly C; Lamarca-Roth E; Lanzone A; Marchand F; Marcolin G; Mascaretti G; Moreau L; Massobrio M; Nappi C; Pardi G; Pennehouat G; Porcu E; Seibert M; Selvaggi L; Thiers D; Venturini P
    Hum Reprod; 2006 Nov; 21(11):2817-22. PubMed ID: 16877376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
    Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
    Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha.
    Barakhoeva Z; Vovk L; Fetisova Y; Marilova N; Ovchinnikova M; Tischenko M; Scherbatyuk Y; Kolotovkina A; Miskun A; Kasyanova G; Teterina T; Zorina I; Belousova N; Morozova E; Yakovenko S; Apryshko V; Sichinava L; Shalinа R; Polzikov M
    Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():6-12. PubMed ID: 31400644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged < 37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study.
    Gholami H; Vicari E; Molis M; La Vignera S; Papaleo E; Cappiello F
    Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):97-102. PubMed ID: 20329567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.